Key Financial Figures - Consolidated (FY26)
- Revenue from Operations: ₹15,548.20 lakhs (vs. ₹7,334.60 lakhs in FY25) - 112% YoY growth
- Total Income: ₹15,809.20 lakhs (vs. ₹7,338.60 lakhs in FY25) - 115% YoY increase
- Net Profit: ₹398.04 lakhs (vs. ₹336.59 lakhs in FY25) - 18.26% YoY growth
- Earnings Per Share (EPS): ₹0.82 per share (vs. ₹0.69 in FY25)
Key Financial Figures - Consolidated (Q4 FY26)
- Revenue from Operations: ₹4,840.70 lakhs (vs. ₹2,235.30 lakhs in Q4 FY25) - 117% YoY growth
- Total Income: ₹4,905.95 lakhs (vs. ₹2,236.00 lakhs in Q4 FY25) - 119% YoY increase
- Net Profit: ₹56.46 lakhs (vs. ₹109.31 lakhs in Q4 FY25)
- Sequential Growth: Revenue from Operations increased from ₹4,453.12 lakhs in Q3 FY26 to ₹4,840.70 lakhs in Q4 FY26 (9% QoQ growth)
- Earnings Per Share (EPS): ₹0.12 per share
Key Financial Figures - Standalone (FY26)
- Revenue from Operations: ₹15,545.08 lakhs
- Total Income: ₹15,806.10 lakhs
- Net Profit: ₹401.88 lakhs
- Earnings Per Share (EPS): ₹0.83 per share
Investments and Subsidiaries
The Company made investments in equity instruments of subsidiaries during the year:
- Aayush Labs Private Limited: ₹25 lakhs
- Aayush Ventures Private Limited: ₹50 lakhs
- Aayush International Pte. Ltd (International Subsidiary): SGD 10,000
Balance Sheet Position (Consolidated as of March 31, 2026)
- Total Assets: ₹1,751.94 lakhs (vs. ₹864.72 lakhs previous year)
- Equity Share Capital: ₹486.72 lakhs
- Reserve & Surplus: ₹739.44 lakhs (vs. ₹341.37 lakhs previous year)
- Borrowings: ₹473.53 lakhs (vs. ₹4.53 lakhs previous year)
- Cash and Cash Equivalents: ₹226.62 lakhs (vs. ₹43.34 lakhs previous year)
Business Update and Strategy
The company strengthened its positioning as an integrated healthcare and wellness company through expansion across preventive healthcare, nutraceuticals, wellness solutions, and condition-specific healthcare products. The company expanded its wellness portfolio through multiple product launches, including immunity, brain health, sleep, and liver care solutions (specifically mentioned "Liver Detox Tablets").
Management Commentary
Naveena Kumar, Managing Director, stated: "FY26 was a year of strong operational growth and strategic expansion for Aayush Wellness Limited. During the year, we continued to strengthen our presence across preventive healthcare and wellness categories through product innovation, expanding distribution, and consumer-focused healthcare solutions."
Dividend Information
The company paid an interim dividend of ₹0.025 per equity share (face value of ₹1 each) for the quarter ended June 30, 2025.
Auditor Change
The company noted that M/s. A J M S & Co. LLP, Chartered Accountants resigned as Statutory Auditors on February 14, 2026, due to increasing professional commitments, and were replaced by A. Raghavendra Rao & Associates.